10-Q: Patterson Companies Net Sales Decline 2.7% in Q3 Amidst Merger Agreement with Patient Square Capital

Patterson Companies reports a decrease in net sales for the third quarter of fiscal year 2025, while navigating a pending merger with Patient Square Capital.

Summary

• Patterson Companies, Inc. reported a 2.7% decrease in net sales for the three months ended January 25, 2025, totaling $1,572.4 million compared to $1,616.1 million in the same period last year.
• Dental segment net sales decreased by 6.4% to $596.3 million, while Animal Health segment net sales increased slightly by 0.5% to $972.4 million.
• The company's gross profit margin rate decreased by 130 basis points to 20.4%, primarily due to margin pressure in the Dental segment.
• Operating income decreased to $45.4 million, or 2.9% of net sales, compared to $70.0 million, or 4.3% of net sales, in the prior year quarter.
• Net income attributable to Patterson Companies, Inc. was $31.3 million, or $0.35 per diluted share, compared to $47.7 million, or $0.52 per diluted share, in the prior year quarter.
• The company is currently undergoing a merger with Paradigm Parent, LLC, an indirect subsidiary of Patient Square Capital, expected to close in April 2025, with each share of common stock being converted into the right to receive $31.35 per share in cash.
• Due to the merger agreement, Patterson did not declare a dividend in the current quarter and does not anticipate further dividend payments during the pendency of the merger.
• For the nine months ended January 25, 2025, consolidated net sales were $4,788.5 million, a 1.2% decrease from $4,845.6 million for the nine months ended January 27, 2024.
• Net income attributable to Patterson Companies, Inc. for the nine months ended January 25, 2025 was $71.7 million, compared to $118.9 million for the nine months ended January 27, 2024.
• Earnings per diluted share were $0.81 in the current period compared to $1.26 in the prior year period for the nine month period.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the decline in sales and profitability, but the pending merger provides some optimism. The Change Healthcare cyber attack and related litigation add to the negative sentiment.

Positives

• Animal Health segment net sales experienced a slight increase of 0.5%.
• The company sold its investment in Vetsource for $86.4 million, resulting in a pre-tax gain of $3.8 million.
• The company acquired Infusion Concepts Limited and Mountain Vet Supply, expanding its portfolio in the Animal Health segment.
• The waiting period for the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has now expired.
• Closing of the Merger is not subject to a financing condition.

Negatives

• Consolidated net sales decreased by 2.7% in Q3 2025.
• Dental segment net sales decreased by 6.4%.
• The consolidated gross profit margin rate decreased by 130 basis points to 20.4%.
• Operating income decreased from $70.0 million to $45.4 million.
• Net income attributable to Patterson Companies, Inc. decreased from $47.7 million to $31.3 million.
• Earnings per diluted share decreased from $0.52 to $0.35.
• The Change Healthcare cyber attack negatively impacted the Dental segment's value-added services category.
• Restructuring activities resulted in pre-tax asset impairment charges of $6.9 million and pre-tax severance charges of $3.3 million.

Risks

• The proposed merger is subject to shareholder approval and other closing conditions, which may not be satisfied.
• The merger could disrupt current plans and operations and divert management's attention.
• The company's stock price may decline significantly if the merger is not consummated.
• The company is subject to restrictions on its business activities while the merger is pending.
• The company faces risks related to the highly competitive dental and animal health supply markets.
• The company is exposed to risks associated with information systems, software products, and cyber-security attacks.
• The company is subject to risks of litigation and government inquiries and investigations.
• The company is exposed to uncertain macro-economic conditions, including inflationary pressures.
• The Change Healthcare cyber attack continues to affect the business and has generated litigation.

Future Outlook

The company is focused on completing the merger with Patient Square Capital, which is expected to close in April 2025. The company expects the collection of deferred purchase price receivables, existing cash balances and credit availability under existing debt facilities, less our funds used in operations, will be sufficient to meet our working capital needs and to finance our business over the remainder of fiscal 2025.

Industry Context

The dental and animal health supply markets are highly competitive and subject to consolidation, which can impact Patterson Companies' performance. The company also faces risks from the formation or expansion of GPOs, provider networks, and buying groups.

Comparison to Industry Standards

• It is difficult to compare Patterson Companies' results directly to industry standards without specific competitor data.
• However, the decline in net sales and gross profit margin suggests that the company is underperforming compared to some of its peers.
• Companies like Henry Schein, Inc. and MWI Animal Health are major competitors in the dental and animal health supply markets, respectively.
• Comparing Patterson's growth rates, profitability, and market share to these companies would provide a better understanding of its relative performance.

Legal Proceedings

• The company is involved in a class action complaint related to the Change Healthcare cyber attack.
• The company has received several demand letters from purported shareholders of the Company alleging failures to disclose material information in the preliminary proxy statement filed by the Company with the SEC in connection with the proposed Merger.

Stakeholder Impact

• Shareholders will receive $31.35 per share in cash upon completion of the merger.
• Employees may experience uncertainty about their roles following the merger.
• Customers may be affected by changes in the company's business operations during the pendency of the merger.
• Suppliers may defer decisions concerning working with the company or seek to change existing business relationships.

Next Steps

• The company will focus on completing the merger with Patient Square Capital, expected to close in April 2025.
• The company will continue to manage costs and enhance efficiency.
• The company will pursue reimbursement under its business interruption insurance policy for losses incurred related to the Change Healthcare cyber attack.
• The company will evaluate the impact of new accounting pronouncements.

Key Dates